ArticleEmerging infectious diseases2019
Mucosal Leishmaniasis in Travelers with Leishmania braziliensis Complex Returning to Israel.
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Cutaneous leishmaniasis in sub-Saharan Africa: a systematic review of Leishmania species, vectors and reservoirs.Parasites & vectors · 2024Pooled it
- Evaluation of Pediatric Patients Diagnosed with Cutaneous Leishmaniasis: A Single-Center Experience.Tropical medicine and infectious disease · 2026Article
- Evidence Gaps and Global Patterns in Leishmaniasis Control: A Scoping Review of Clinical, Diagnostic, and Treatment Strategies.Journal of parasitology research · 2026Review
- Human migrations, anthropogenic changes, and insect-borne diseases in Latin America.Parasites & vectors · 2025Review
- The Epidemiology of PCR-Confirmed Cutaneous Leishmaniasis in Israel: A Nationwide Study.Microorganisms · 2024Article
- Self-application of aminoglycoside-based creams to treat cutaneous leishmaniasis in travelers.PLoS neglected tropical diseases · 2023Article
- Factors associated with mucosal involvement in tegumentary leishmaniasis: a nation-based study using surveillance data from Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2023Article
- Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.Pathogens (Basel, Switzerland) · 2022Review
- Gender and Cutaneous Leishmaniasis in Israel.Tropical medicine and infectious disease · 2022Article
- Leishmania RNA virus-1 is similarly detected among metastatic and non-metastatic phenotypes in a prospective cohort of American Tegumentary Leishmaniasis.PLoS neglected tropical diseases · 2022Article
- Article
- Clinical diversity and treatment results in Tegumentary Leishmaniasis: A European clinical report in 459 patients.PLoS neglected tropical diseases · 2021Observational
- Case Report: Mucosal Leishmaniasis in New York City.The American journal of tropical medicine and hygiene · 2020Article
- Cannabis, One Health, and Veterinary Medicine: Cannabinoids' Role in Public Health, Food Safety, and Translational Medicine.Rambam Maimonides medical journal · 2020Review
- Relevance of epidemiological surveillance in travelers: an imported case of Leishmania tropica in Mexico.Revista do Instituto de Medicina Tropical de Sao Paulo · 2020Article
- Cutaneous and mucocutaneous leishmaniasis in travellers and migrants: a 20-year GeoSentinel Surveillance Network analysis.Journal of travel medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucosal leishmaniasis (ML) is a complication of New World cutaneous leishmaniasis (CL) caused mainly by Leishmania (Viannia) braziliensis. This retrospective study investigated all cases of ML caused by L. (V.) braziliensis in a tertiary medical center in Israel, evaluating the risk factors, clinical presentations, diagnosis, treatment, and outcome of mucosal involvement in ML caused by L. (V.) braziliensis in travelers returning to Israel. During 1993-2015, a total of 145 New World CL cases were seen in travelers returning from Bolivia; among them, 17 (11.7%) developed ML. Nasopharyngeal symptoms developed 0-3 years (median 8 months) after exposure. The only significant risk factor for developing ML was the absence of previous systemic treatment. Among untreated patients, 41% developed ML, compared with only 3% of treated patients (p = 0.005). Systemic treatment for CL seems to be a protective factor against developing ML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.